A first in human study of ASX-100
Latest Information Update: 26 Feb 2021
At a glance
- Drugs ASX-100 (Primary)
- Indications Adult respiratory distress syndrome
- Focus Adverse reactions; First in man
- 26 Feb 2021 New trial record
- 23 Feb 2021 According to an Asalyxa Bio media release, the financing which was led by Research Bridge Partners, co-led by ID Ventures, and also included Michigan Rise Pre-Seed Fund III, BRCC of Western Michigan University, Ann Arbor Spark, Woodward Angels and other undisclosed investors will be used to advance this first in human study in 2021.